Literature DB >> 12123788

18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.

Yann Seimbille1, Jacques Rousseau, François Bénard, Catherine Morin, Hasrat Ali, George Avvakumov, Geoffrey L Hammond, Johan E van Lier.   

Abstract

A-ring fluorination of estradiol (ES) at position 2 or 4 decreases the rate of metabolism by blocking the formation of catechol estrogens, one of the major metabolic pathways of ES. We postulate that adding a 2- or 4-fluoro substituent to 16alpha-[18F]fluoroestradiol (FES), a positron emission tomography (PET) radiopharmaceutical used for estrogen receptor (ER) imaging, should prolong its blood circulation time, and thus, improve its localization in ER-rich target tissues. On such account, we prepared a series of FES derivatives substituted with a fluorine atom at C2 or C4, with or without an 11beta-OMe group, and we tested their binding affinities for the ER and different serum proteins including rat alphafetoprotein (AFP) and human sex hormone-binding globulin (SHBG). Labeling at the 16alpha-position was accomplished via nucleophilic substitution with [18F]F(-) on the reactive 16beta,17beta-cyclic sulfate intermediates. Decay corrected yields varied between 30 and 50% for a total synthesis time of 120 min, providing final products with specific activities >3000 Ci/mmol. The 18F-labeled analogs were evaluated for their biodistribution in immature female rats. Substitutions with the 4-F have little effect on binding affinities. Addition of the 2-F diminishes ER and AFP-binding affinities while augmenting the affinity for the SHBG. Addition of the 11beta-OMe decreases all binding affinities, particularly to AFP and SHBG. In contrast, biodistribution of the corresponding [16alpha-18F]fluoro analogs in immature female rats revealed that the presence of the 11beta-OMe group improves ER-mediated uterus uptake, with the 4,16alpha-[16alpha-18F]difluoro-11beta-methoxyestradiol showing the highest uptake values (15% ID at 1-h post-injection). These data suggest that the addition of both a 4-F and 11beta-OMe group onto FES may provide an improved radiopharmaceutical for PET imaging of ER densities in breast cancer patients. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12123788     DOI: 10.1016/s0039-128x(02)00025-9

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  16 in total

Review 1.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

2.  Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions.

Authors:  Markus Rudin
Journal:  Eur Radiol       Date:  2007-03-06       Impact factor: 5.315

3.  Design, synthesis, and evaluation of cyclofenil derivatives for potential SPECT imaging agents.

Authors:  Hua Zhu; Liliang Huang; Yuanqing Zhang; Xiaoping Xu; Yanhong Sun; Yu-Mei Shen
Journal:  J Biol Inorg Chem       Date:  2010-03-01       Impact factor: 3.358

4.  Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.

Authors:  Michel Paquette; Éric Lavallée; Serge Phoenix; René Ouellet; Helena Senta; Johan E van Lier; Brigitte Guérin; Roger Lecomte; Éric E Turcotte
Journal:  J Nucl Med       Date:  2017-08-10       Impact factor: 10.057

5.  Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results.

Authors:  T A Heusner; S Hahn; C Jonkmanns; S Kuemmel; F Otterbach; M E Hamami; A R Stahl; A Bockisch; M Forsting; G Antoch
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

Review 6.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

7.  Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.

Authors:  Michel Paquette; Serge Phoenix; René Ouellet; Réjean Langlois; Johan E van Lier; Eric E Turcotte; Francois Bénard; Roger Lecomte
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

8.  [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice.

Authors:  François Bénard; Naseem Ahmed; Jean-Mathieu Beauregard; Jacques Rousseau; Antonio Aliaga; Céléna Dubuc; Etienne Croteau; Johan E van Lier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-13       Impact factor: 9.236

9.  PET Imaging of Estrogen Receptors Using 18F-Based Radioligands.

Authors:  Manoj Kumar; Kelley Salem; Justin J Jeffery; Amy M Fowler
Journal:  Methods Mol Biol       Date:  2022

10.  An in vitro and in vivo evaluation of a reporter gene/probe system hERL/(18)F-FES.

Authors:  Chunxia Qin; Xiaoli Lan; Jiang He; Xiaotian Xia; Yueli Tian; Zhijun Pei; Hui Yuan; Yongxue Zhang
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.